康为世纪（688426.SH）11月20日在投资者互动平台表示，尊敬的投资者您好。公司已经获得欧盟CE- IVDR认证，并且出口欧盟多个国家，例如克罗地亚，意大利，斯洛伐克，匈牙利等。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司近两年是否出口欧盟国家？ ...

Core Viewpoint - 康为世纪 experienced a 5.13% increase in stock price, reaching 32.80 yuan per share, with a total market capitalization of 3.69 billion yuan as of November 17 [1] Company Overview - 江苏康为世纪生物科技股份有限公司 was established on September 3, 2010, and went public on October 25, 2022 [1] - The company specializes in the research, production, and sales of molecular detection products, providing molecular detection services [1] - Revenue composition: 89.14% from product sales, 10.86% from services, and 0.00% from other sources [1] Shareholder Analysis - 融通健康产业灵活配置混合A/B (000727) reduced its holdings by 1 million shares in Q3, now holding 2.6 million shares, representing 6.84% of the circulating shares [2] - The fund has achieved a year-to-date return of 16.85% and a one-year return of 6.21% [2] - The fund manager, 万民远, has a tenure of 9 years and 86 days, with a total fund size of 5.96 billion yuan [2][4] Fund Holdings - 融通价值成长混合A (015553) reduced its holdings by 50,000 shares in Q3, currently holding 450,000 shares, which is 3.05% of the fund's net value [3] - The fund has a year-to-date return of 24.83% and a one-year return of 19.23% [3] - The fund manager, 万民远, has a tenure of 9 years and 86 days, managing a total fund size of 5.96 billion yuan [4]

资料显示，江苏康为世纪生物科技股份有限公司位于江苏省泰州市医药高新区泽兰路18号，成立日期 2010年9月3日，上市日期2022年10月25日，公司主营业务涉及分子检测产品的研发、生产和销售,并提 供分子检测服务。主营业务收入构成为：销售商品89.14%，提供服务10.86%，其他(补充)0.00%。 从基金十大重仓股角度 11月17日，康为世纪涨5.13%，截至发稿，报32.80元/股，成交3710.07万元，换手率3.12%，总市值 36.90亿元。 数据显示，东证资管旗下1只基金重仓康为世纪。东方红量化选股混合发起A（020803）三季度持有股 数2.95万股，占基金净值比例为2.47%，位居第十大重仓股。根据测算，今日浮盈赚取约4.72万元。 东方红量化选股混合发起A（020803）成立日期2024年5月21日，最新规模2437.04万。今年以来收益 15.23%，同类排名5160/8213；近一年收益14.44%，同类排名4843/8130；成立以来收益19.84%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、 ...

Core Viewpoint - The medical device sector experienced a slight decline of 0.31% on November 6, with Danaher Biomedical leading the losses, while the overall market indices showed gains, with the Shanghai Composite Index up by 0.97% and the Shenzhen Component Index up by 1.73% [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4007.76, increasing by 0.97% [1]. - The Shenzhen Component Index closed at 13452.42, increasing by 1.73% [1]. - The medical device sector saw a net outflow of 638 million yuan from major funds, while retail investors contributed a net inflow of 446 million yuan [2][3]. Group 2: Individual Stock Performance - Hualan Co., Ltd. (301093) saw a significant increase of 8.53%, closing at 44.00 yuan with a trading volume of 67,500 shares and a transaction value of 293 million yuan [1]. - Danaher Biomedical (920009) led the declines with a drop of 4.69%, closing at 83.50 yuan and a trading volume of 24,900 shares, resulting in a transaction value of 206 million yuan [2]. - Other notable gainers included Furuida (300049) with a 4.32% increase and a closing price of 74.56 yuan, and Kangzhong Medical (688607) with a 3.04% increase, closing at 29.81 yuan [1][2]. Group 3: Fund Flow Analysis - Major funds showed a net outflow in several stocks, including Furuida with a net outflow of 23.99 million yuan, while retail investors showed a net inflow of 25.27 million yuan [3]. - Dongfulong (300171) experienced a net inflow of 21.17 million yuan from major funds, indicating positive sentiment towards the stock [3]. - The overall trend indicates a mixed sentiment in the medical device sector, with some stocks attracting retail interest despite the overall outflow from major funds [2][3].

Core Insights - 康为世纪 is a leading provider of molecular detection solutions in China, established in 2010 and listed on the Shanghai Stock Exchange in 2022 [1] Financial Performance - In Q3 2025, 康为世纪 reported revenue of 140 million yuan, ranking 36th among 39 companies in the industry, with the industry leader generating 3.428 billion yuan [2] - The company's net profit for the same period was -78.1 million yuan, placing it 31st in the industry, while the top performer reported a net profit of 1.588 billion yuan [2] Profitability and Debt - 康为世纪's debt-to-asset ratio was 9.14% in Q3 2025, lower than the industry average of 18.29% [3] - The gross profit margin for the company was 49.78%, which is below the industry average of 56.20% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.11% to 3,905, while the average number of circulating A-shares held per shareholder increased by 1.13% to 9,729.41 [5] - The largest circulating shareholder, 融通健康产业灵活配置混合A/B, reduced its holdings by 1 million shares [5] Executive Compensation - The chairman and general manager, 王春香, received a salary of 1.205 million yuan in 2024, a decrease of 160,000 yuan from 2023 [4]

Core Insights - The company reported a revenue of 140 million yuan for the first three quarters of 2025, representing a year-on-year growth of 42.01% [1] - The company experienced a net loss attributable to shareholders of 76.16 million yuan [1] - The company's net profit excluding non-recurring items was a loss of 93.91 million yuan [1] - The basic earnings per share were reported at -0.69 yuan [1]

Core Viewpoint - Kangwei Century (688426.SH) reported a significant increase in revenue for the first three quarters of 2025, indicating strong growth potential despite ongoing losses [1] Financial Performance - The company achieved total operating revenue of 140 million yuan, representing a year-on-year increase of 42.01% [1] - The net profit attributable to shareholders of the parent company was -76.1626 million yuan, which is a reduction in losses by 19.4888 million yuan compared to the same period last year [1] - The basic earnings per share stood at -0.69 yuan [1]

证券代码：688426 证券简称：康为世纪 公告编号：2025-043 江苏康为世纪生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2025 年 11 月 10 日（星期一）下午 16:00-17:00 1 / 3 ●会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com） ●会议召开方式：上证路演中心网络互动 ●投资者可于 2025 年 11 月 3 日（星期一）至 2025 年 11 月 7 日（星期五）中午 12:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IRM@cwbio.cn 进行提问。公司将在本次业绩说明会上对投资者普遍关注的、有代表性的问题逐条进行 回答。 江苏康为世纪生物科技股份有限公司(下称"公司")已于 2025 年 10 月 31 日在上海证 券交易所网站（www.sse.com.cn）披露了《2025 年第三季度报告》，为了 ...

Financial Performance - Revenue for Q3 2025 reached ¥52,455,562.72, an increase of 68.47% compared to the same period last year[3] - Total profit for Q3 2025 was -¥21,249,963.37, representing a decrease of 54.96% year-on-year[3] - Net profit attributable to shareholders for Q3 2025 was -¥20,251,462.35, a decline of 55.58% compared to the previous year[3] - Operating cash flow for Q3 2025 was -¥22,168,904.60, a decrease of 34.03% year-on-year[3] - Total operating revenue for the first three quarters of 2025 reached ¥139,574,234.46, a significant increase from ¥98,283,588.99 in the same period of 2024, representing a growth of approximately 42%[18] - The operating profit for the first three quarters of 2025 was reported at -¥79,256,667.56, an improvement compared to -¥104,752,492.00 in 2024[19] - Net profit for the first three quarters of 2025 was -¥78,096,679.32, compared to -¥95,907,697.78 in the same period of 2024, indicating a reduction in losses[19] - The total comprehensive income attributable to the parent company was -76,162,854.28 CNY, compared to -95,645,454.09 CNY in the previous period, showing an improvement[20] - The company reported a basic and diluted earnings per share of -0.69 CNY, an improvement from -0.86 CNY in the prior period[20] Research and Development - R&D expenses totaled ¥18,092,442.60 in Q3 2025, down 30.50% from the previous year[4] - R&D expenses accounted for 34.49% of revenue in Q3 2025, a decrease of 49.11 percentage points year-on-year[4] - Research and development expenses for the first three quarters of 2025 amounted to ¥58,902,293.52, down from ¥72,049,404.79 in 2024, showing a decrease of approximately 18%[18] - The company optimized R&D resource allocation, focusing on market-oriented projects to enhance efficiency[8] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥1,550,833,825.96, a decrease of 4.16% from the end of the previous year[4] - Total liabilities increased to ¥141,692,635.09 from ¥131,788,713.04, marking an increase of about 7%[14] - The total equity attributable to shareholders decreased to ¥1,390,519,558.42 from ¥1,465,785,417.74, reflecting a decline of approximately 5.1%[14] - Cash and cash equivalents included in current assets totaled ¥1,087,753,273.02, compared to ¥833,404,226.85 in the previous period, indicating a growth of about 30.5%[15] - The company reported a decrease in short-term borrowings to ¥10,007,777.78 from ¥6,005,600.00, reflecting a strategic reduction in debt[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 3,905[10] - Beijing Kangwei Century Biotechnology Co., Ltd. holds 50,400,000 shares, accounting for 44.80% of total shares[10] - Taizhou Kangwei Co-Creation Enterprise Management Consulting Partnership holds 21,600,000 shares, representing 19.20% of total shares[10] - The top ten shareholders do not include any shares lent through margin trading[12] - The company has no significant changes in shareholder structure compared to the previous period[12] Cash Flow - The company's cash and cash equivalents as of September 30, 2025, amount to ¥184,205,974.30, down from ¥255,466,049.27 as of December 31, 2024[12] - The net cash flow from operating activities was -71,824,555.68 CNY, an improvement from -92,827,326.52 CNY year-over-year[21] - Cash received from the sale of goods and services increased to 126,143,516.94 CNY, up from 90,526,995.55 CNY in the same period last year, representing a growth of approximately 39.2%[21] - The company incurred operating cash outflows totaling 229,309,685.83 CNY, compared to 189,799,092.17 CNY in the previous year[21] - The company received cash inflows from investment activities totaling 1,219,429,294.81 CNY, compared to 707,660,113.86 CNY in the previous year[21] - The company’s cash outflows from financing activities were 14,202,559.75 CNY, compared to 54,328,194.97 CNY in the previous year, indicating a reduction in financing costs[21] Operational Highlights - The increase in revenue was primarily driven by significant growth in nanopore sequencing services[8] - There are no other important reminders regarding the company's operational situation during the reporting period[12] - The company did not execute any mergers or acquisitions during the reporting period[20]

证券代码：688426 证券简称：康为世纪 公告编号：2025-042 江苏康为世纪生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 10 月 29 日 （二） 股东会召开的地点：江苏省泰州市医药高新区泽兰路 18 号江苏康为世纪 生物科技股份有限公司 2 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 35 | | --- | --- | | 普通股股东人数 | 35 | | 2、出席会议的股东所持有的表决权数量 | 78,019,730 | | 普通股股东所持有表决权数量 | 78,019,730 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 70.9710 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 7 ...